{
    "clinical_study": {
        "@rank": "35228", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients will receive continuous intravenous infusion of matching placebo serelaxin for 48 hours."
            }, 
            {
                "arm_group_label": "Serelaxin", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive continuous intravenous infusion of serelaxin for 48 hours."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the efficacy, safety and tolerability of intravenous\n      infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF)\n      patients."
        }, 
        "brief_title": "Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female  \u2265 18 years of age, with body weight  \u2264160 kg\n\n          -  Hospitalized for AHF; AHF is defined as including all of the following measured at\n             any time between presentation (including the emergency department) and the end of\n             screening:\n\n               -  Dyspnea at rest or with minimal exertion\n\n               -  Pulmonary congestion on chest radiograph\n\n               -  Brain natriuretic peptide (BNP) \u2265350 pg/mL or NT-proBNP \u22651,400 pg/mL\n\n          -  Systolic BP \u2265125 mmHg at the start and at the end of screening\n\n          -  Able to be randomized within 16 hours from presentation to the hospital, including\n             the emergency department\n\n          -  Received intravenous furosemide of at least 40 mg total (or equivalent) at any time\n             between presentation (this includes outpatient clinic, ambulance, or hospital\n             including emergency department) and the start of screening for the study for the\n             treatment of the current acute HF episode\n\n          -  Renal impairment defined as an estimate glomerular filtration rate using the  between\n             presentation and randomization of \u2265 25 and \u226475mL/min/1.73m2, calculated using the\n             Modification of Diet in Renal Disease formula.\n\n        Exclusion Criteria:\n\n          -  Dyspnea primarily due to non-cardiac causes\n\n          -  Temperature >38.5\u00b0C (oral or equivalent) or sepsis or active infection requiring IV\n             anti-microbial treatment\n\n          -  Clinical evidence of acute coronary syndrome currently or within 30 days prior to\n             enrollment\n\n          -  AHF due to significant arrhythmias, which include any of the following: sustained\n             ventricular tachycardia, bradycardia with sustained ventricular rate <45 beats per\n             minute, or atrial fibrillation/flutter with sustained ventricular response of >130\n             beats per minute\n\n          -  Hepatic disease unrelated to Heart Failure etiology and as determined by any one of\n             the following: AST and/or ALT values exceeding 3 X ULN and/or bilirubin > 1.5 X ULN\n             at screening or  history of hepatic encephalopathy, esophageal varices, or portacaval\n             shunt, or a diagnosis of cirrhosis by any means, or evidence of chronic Hepatitis B\n             (presence of hepatitis B surface antigen production: positive HBsAg), or chronic\n             Hepatitis C infection (presence of Hepatitis C genetic replication: positive\n             Hepatitis C viral  RNA, based on history and/or clinical findings, including\n             laboratory results obtained during screening period).\n\n        Other protocol defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1520", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02007720", 
            "org_study_id": "CRLX030A2302"
        }, 
        "intervention": [
            {
                "arm_group_label": "Serelaxin", 
                "description": "Intravenous infusion", 
                "intervention_name": "Serelaxin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Intravenous infusion", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Placebo", 
                    "Serelaxin"
                ], 
                "description": "This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, \u03b2 blockers, and aldosterone receptor antagonists, etc.", 
                "intervention_name": "Standard of CareTherapy", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Angiotensin Receptor Antagonists", 
                "Aldosterone Antagonists"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Serelaxin", 
            "WHF", 
            "Likert Scale"
        ], 
        "lastchanged_date": "April 9, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Cheongju", 
                        "country": "Korea, Republic of", 
                        "state": "Chungbuk", 
                        "zip": "361 711"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wonju", 
                        "country": "Korea, Republic of", 
                        "state": "Gangwon", 
                        "zip": "220-701"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dong-gu", 
                        "country": "Korea, Republic of", 
                        "state": "Gwangju", 
                        "zip": "501-575"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Korea", 
                        "zip": "135-710"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Korea", 
                        "zip": "110 744"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bundang", 
                        "country": "Korea, Republic of", 
                        "state": "Seongnam", 
                        "zip": "463-707"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of", 
                        "zip": "602-739"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "738-736"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "120-752"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kota Kinabalu", 
                        "country": "Malaysia", 
                        "state": "Sabah", 
                        "zip": "88300"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kuching", 
                        "country": "Malaysia", 
                        "state": "Sarawak", 
                        "zip": "94300"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kuala Lumpur", 
                        "country": "Malaysia", 
                        "state": "Selangor Darul Ehsan", 
                        "zip": "43000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sungai Buloh", 
                        "country": "Malaysia", 
                        "state": "Selangor Darul Ehsan", 
                        "zip": "47000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kuala Lumpur", 
                        "country": "Malaysia", 
                        "zip": "56000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kuala Lumpur", 
                        "country": "Malaysia", 
                        "zip": "59100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kuala Lumpur", 
                        "country": "Malaysia", 
                        "zip": "50400"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manila", 
                        "country": "Philippines", 
                        "zip": "1000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manila", 
                        "country": "Philippines", 
                        "zip": "1004"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manila", 
                        "country": "Philippines", 
                        "zip": "1008"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pasig City", 
                        "country": "Philippines", 
                        "zip": "1605"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quezon City", 
                        "country": "Philippines", 
                        "zip": "1113"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quezon City", 
                        "country": "Philippines", 
                        "zip": "1102"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quezon City", 
                        "country": "Philippines", 
                        "zip": "1100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Juan City", 
                        "country": "Philippines", 
                        "zip": "1500"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore", 
                        "zip": "168752"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore", 
                        "zip": "308433"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10400"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10330"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10700"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiang Mai", 
                        "country": "Thailand", 
                        "zip": "50200"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Muang", 
                        "country": "Thailand", 
                        "zip": "40002"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Songkla", 
                        "country": "Thailand", 
                        "zip": "90110"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Korea, Republic of", 
                "Malaysia", 
                "Philippines", 
                "Singapore", 
                "Thailand"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Randomized, Double-blind, Placebo Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Singapore: Health Sciences Authority", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The trichotomous clinical composite endpoint of treatment success, treatment failure, or no change. Treatment success defined as improvement of dyspnea by Likert scale and at least 2 points improvement by at least 2 physician assessed signs and symptoms (orthopnea, rales edema, and jugular venous pulse) at Day 2; treatment failure defined as worsening heart failure, death, or re-hospitalization due to heart failure or renal failure through Day 5; no change defined as neither the criteria for treatment success nor the criteria for treatment failure was met through Day 5.", 
            "measure": "Percentage of patients with a clinical composite endpoint of treatment success, treatment failure, or no change.", 
            "safety_issue": "No", 
            "time_frame": "Treatment success at Day 2, Treatment failure through Day 5, and No change through Day 5"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02007720"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Time to event is computed as the number of days from randomization to Worsening Heart Failure", 
                "measure": "Time to Worsening Heart Failure", 
                "safety_issue": "No", 
                "time_frame": "Through Day 5"
            }, 
            {
                "description": "Time to event is computed as the number of days from randomization to cardiovascular death", 
                "measure": "Time to cardiovascular death", 
                "safety_issue": "No", 
                "time_frame": "Through Day 180"
            }, 
            {
                "description": "Time to event is computed as the number of days from randomization to all cause death", 
                "measure": "Time to all-cause death", 
                "safety_issue": "No", 
                "time_frame": "Through Day 180"
            }, 
            {
                "description": "Time to event is computed as the number of days from randomization to moderate or marked improvements in dyspnea by Likert scale", 
                "measure": "Time to moderate or marked improvements in dyspnea by Likert scale", 
                "safety_issue": "No", 
                "time_frame": "Through Day 5"
            }, 
            {
                "description": "Change from baseline in Dyspena by VAS-AUC through Day 5", 
                "measure": "Dyspnea by VAS-AUC changes", 
                "safety_issue": "No", 
                "time_frame": "Through Day 5"
            }, 
            {
                "description": "Length of stay will be defined as the hospitalization discharge date and the time minus the baseline date and time plus 1 day", 
                "measure": "Length of Intensive Care Unit (ICU) and/or Coronary Care Unit (CCU) stay for the index AHF hospitalization", 
                "safety_issue": "No", 
                "time_frame": "Up to day 30"
            }, 
            {
                "measure": "Renal dysfunction and prevention of worsening of renal function", 
                "safety_issue": "No", 
                "time_frame": "Through Day 5"
            }, 
            {
                "description": "Time to event is computed as the number of days from randomization to re-hospitalization due to Heart Failure and renal impairment", 
                "measure": "Time to re-hospitalization due to Heart Failure and renal impairment", 
                "safety_issue": "No", 
                "time_frame": "Through Day 180"
            }, 
            {
                "description": "Time to event is computed as the number of days from randomization to CV death or re-hospitalization due to Heart Failure", 
                "measure": "Time to CV death or re-hospitalization due to Heart Failure/ Renal Failure", 
                "safety_issue": "No", 
                "time_frame": "Through Day 180"
            }, 
            {
                "description": "Number of patients reported with use of loop diuretic and vasoactive agents from randomization through Day 5", 
                "measure": "Use of loop diuretic and vasoactive agents", 
                "safety_issue": "No", 
                "time_frame": "Through Day 5"
            }, 
            {
                "measure": "Change from baseline in cardio-renal biomarkers", 
                "safety_issue": "No", 
                "time_frame": "Day 2 and Day 5"
            }, 
            {
                "description": "To evaluate the safety and tolerability of intravenous serelaxin in AHF patients, number of patients with total adverse events, serious adverse events and death will be analyzed.", 
                "measure": "Number of patients reported with total adverse events, serious adverse events and death.", 
                "safety_issue": "Yes", 
                "time_frame": "For the safety evaluation, all adverse events will be collected from signing of the informed consent form through Day 5 for non-serious AEs and through Day 14 for serious AEs."
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}